Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Clearmind Medicine Inc. (CMND)
Clearmind Medicine Welcomes Executive Order On Psychedelic Therapies
4/20/2026 10:10:54 PM
Clearmind Medicine Soars 70% On Positive AUD Trial Results
4/20/2026 10:48:22 AM
Clearmind Medicine Says CMND-100 Meets Primary Goal In Early AUD Study; Stock Up In Pre-Market
4/20/2026 8:14:42 AM
Clearmind Medicine Announces Positive Phase I/IIa Results For CMND-100 For The Treatment Of Alcohol Use Disorder
4/20/2026 7:19:38 AM
Clearmind Medicine's CMND-100 Trial Clears Safety Review For Alcohol Use Disorder
4/15/2026 10:38:16 PM
Clearmind Medicine Receives Positive DSMB Recommendation For CMND-100
4/15/2026 7:44:04 AM
Clearmind's CMND-100 Hits Primary Endpoint In Alcohol Use Disorder; Stock Down
4/14/2026 11:29:45 AM
Clearmind Completed Treatment And Follow-Up For 18 Participants In CMND-100 Trial For AUD
3/31/2026 12:56:37 AM
Clearmind Reports Progress In CMND-100 AUD Trial; Stock Down
3/19/2026 10:14:37 AM
Clearmind Advances Phase I/IIa Trial Of CMND-100 For Alcohol Use Disorder
3/19/2026 8:59:56 AM
Clearmind Proceeds Recruitment For Third Cohort Of Phase I/IIa Trial Of CMND-100 In AUD
3/12/2026 4:02:58 AM
Clearmind Announces Continuation Of Participant Enrollment In Alcohol Use Disorder Trial
3/11/2026 9:12:58 AM
Clearmind Medicine Announces Additional Positive Safety Topline Data From CMND-100 Study
2/9/2026 8:42:29 AM
Clearmind Reports Addnl. Positive Results From Phase I/IIa CMND-100 Trial In Alcohol Use Disorder
2/9/2026 8:25:15 AM
Clearmind Reports Positive Results From Second Cohort In Phase I/IIa Trial Of CMND-100 For Alcohol Use Disorder;stock Up
2/9/2026 8:21:29 AM
Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders
2/6/2026 9:36:49 AM
Polyrizon And Clearmind Partner To Develop Intranasal MEAI Formulation For Addiction And CNS Disorders
2/6/2026 8:17:55 AM
Clearmind Partners With Polyrizon To Advance MEAI Candidate For Addiction And CNS Disorders
2/6/2026 8:16:51 AM
Clearmind Medicine Enters Development Agreement With Polyrizon To Advance Intranasal Delivery Solutions
2/6/2026 8:16:51 AM
Older Articles